SCHEMBL3614020

SCHEMBL3614020

NC1=NC(C2CCCCC2)CO1

nearest known ligand 0.50

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 4/20 0.47
NOS2 P35228 3/20 0.47
NOS3 P29474 2/20 0.44
TAAR1 Q96RJ0 5/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3614022 1.00 NOS1 (0.47) NOS1NOS2NOS3TAAR1
SCHEMBL31369274 0.78 NOS1 (0.41) NOS1NOS2NOS3
SCHEMBL7856571 0.73 NOS1 (0.37) NOS1NOS2NOS3
SCHEMBL11190048 0.72 NOS1 (0.36) NOS1NOS2NOS3
Hydrochloric Acid SCHEMBL5621770 0.71 NOS1 (0.35) NOS1NOS2NOS3
Bromide SCHEMBL5619566 0.71 NOS1 (0.35) NOS1NOS2NOS3
SCHEMBL3612703 0.67 NOS1 (0.53) NOS1NOS2TAAR1
SCHEMBL3612697 0.67 NOS1 (0.53) NOS1NOS2TAAR1
SCHEMBL15705158 0.67 TAAR1 (0.36) TAAR1
SCHEMBL11816622 0.64 NOS1 (0.40) NOS1NOS2NOS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2114906-B1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS HOFFMANN LA ROCHE (CH) 2014-08-06 EP disclosed
US-8604061-B2 2-aminooxazolines as TAAR1 ligands HOFFMANN-LA ROCHE INC. (US) 2013-12-10 US disclosed
US-20120196903-A1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS GALLEY GUIDO (DE) 2012-08-02 US disclosed
US-20100120864-A1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS GALLEY GUIDO 2010-05-13 US disclosed
EP-2114906-A1 NOVEL 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS F. Hoffmann-Roche AG (CH) 2009-11-11 EP disclosed
US-20080261920-A1 2-Aminooxazolines as TAAR1 ligands F. HOFFMANN-LA ROCHE AG (CH) 2008-10-23 US disclosed
WO-2008092785-A1 NOVEL 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2008-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120864-A1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS TAAR1, TAAR5, NPY2R NOS1 1028/4885NOS2 1357/4885NOS3 1483/4885
US-20120196903-A1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS TAAR1, TAAR5, NPY2R NOS1 1058/4885NOS2 1205/4885NOS3 1381/4885
US-20080261920-A1 2-Aminooxazolines as TAAR1 ligands TAAR1, TAAR5, NPY2R NOS1 1028/4885NOS2 1357/4885NOS3 1483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.